RLYB is tracked by BiotechSign with a current catalyst score of 20/100 and grade F. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Rallybio Corporation (RLYB) has a BiotechSign Catalyst Score of 20/100, rated F. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Rallybio Corporation (RLYB) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.
No Form 4 insider filings for RLYB were recorded at the SEC in the past 30 days[1].